State Street Corp Grows Position in Alto Neuroscience, Inc. (NYSE:ANRO)

State Street Corp boosted its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 123.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 236,857 shares of the company's stock after acquiring an additional 130,985 shares during the period. State Street Corp owned 0.88% of Alto Neuroscience worth $2,710,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. FMR LLC increased its stake in shares of Alto Neuroscience by 1.4% in the 3rd quarter. FMR LLC now owns 2,363,056 shares of the company's stock worth $27,033,000 after acquiring an additional 32,040 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Alto Neuroscience by 80.3% in the third quarter. Jennison Associates LLC now owns 832,290 shares of the company's stock valued at $9,521,000 after purchasing an additional 370,612 shares during the period. Vestal Point Capital LP increased its position in Alto Neuroscience by 4.8% during the third quarter. Vestal Point Capital LP now owns 650,000 shares of the company's stock worth $7,436,000 after purchasing an additional 30,000 shares during the last quarter. Philadelphia Financial Management of San Francisco LLC raised its stake in Alto Neuroscience by 1.5% during the third quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company's stock worth $5,147,000 after purchasing an additional 6,663 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Alto Neuroscience by 182.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company's stock valued at $2,139,000 after purchasing an additional 120,779 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ANRO. Robert W. Baird cut their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. RODMAN&RENSHAW downgraded Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Stifel Nicolaus decreased their price target on Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. Rodman & Renshaw downgraded Alto Neuroscience from a "buy" rating to a "neutral" rating in a research report on Wednesday, October 23rd. Finally, Wedbush cut shares of Alto Neuroscience from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $20.00.

Alto Neuroscience Stock Performance

NYSE:ANRO traded up $0.03 on Wednesday, reaching $4.23. 223,053 shares of the company's stock were exchanged, compared to its average volume of 366,644. Alto Neuroscience, Inc. has a 52-week low of $3.56 and a 52-week high of $24.00. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $4.14 and a 200-day moving average of $9.28.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05. Equities analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.